CB 03
Alternative Names: CB 04; CB-003 - Zhimeng Biopharma; CB-03; CB-04 - Zhimeng Biopharma; CB03-154Latest Information Update: 03 Oct 2024
At a glance
- Originator Zhimeng Biopharma
- Class Analgesics; Antidepressants; Antiepileptic drugs; Small molecules
- Mechanism of Action KCNQ2 potassium channel stimulants; KCNQ3 potassium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Epilepsy
- Preclinical Amyotrophic lateral sclerosis; Depressive disorders; Stroke
- No development reported Pain
Most Recent Events
- 30 Sep 2024 Shanghai Zhimeng Biopharma plans a phase II trial for Partial epilepsies (Adjunctive treatment) in September 2024 (NCT06612775)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Pain in China
- 12 Feb 2024 356394- Trial completion added in KDM and HE